114450.KQ KPX Lifescience.Co.Ltd

Healthcare Pharmaceuticals KOSDAQ
2,653 KRW
Close of Oct 30, 2026
1,673 4,590
Market cap
KRW 39.8B
P/E
-
P/B
0.89x
ROE
27.4%
Dividend yield
-
Fundamental score
2.1/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 114450.KQ undervalued?

Graham number

The Graham number of KPX Lifescience.Co.Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

KPX Lifescience.Co.Ltd fundamental analysis

10 of 22 checks passed

ROE 2/2

High return on equity (27.4%), above 20%.

ROA 1/1

Return on assets (20.7%) is above the industry median (3.4%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (-93.2%) is below the industry median (6.6%).

Revenue Growth 1/2

Revenue grew 3.4% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (3.3%), 40% or less.

Debt Trend 1/1

Debt to equity has not risen over the past 5 years.

Debt Coverage 1/1

Operating cash flow covers 20% of total debt.

Interest Coverage 1/1

EBIT is 28.2x against interest expense, well covered.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 0/1

Price to book (0.9x) is above the industry median (0.8x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

KPX Lifescience.Co.Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About KPX Lifescience.Co.Ltd

KPX Lifescience.Co.,Ltd. engages in development, production, and sale of agrochemical raw materials and pharmaceutical intermediates in South Korea and internationally. The company offers raw materials for pharmaceuticals, pesticides, and primary intermediates to the pharmaceutical and agrochemical markets. It also develops EDP-CL, an intermediate for piperacillin-based antibiotics, including N,N-disuccinimidyl carbonate used for the synthesis of HIV treatment; Amoxapine, an…

Full company profile